News | November 09, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Subscribe To Our Newsletter & Stay Updated
